Characteristics and patterns of healthcare utilization of patients with fibromyalgia in general practitioner settings in Germany

Current Medical Research and Opinion

Volumn 24, Issue 9, 2008, Pages 2489-2499

  Berger, Ariel ^a   Sadosky, Alesia ^b   Dukes, Ellen ^b   Martin, Susan ^b   Edelsberg, John ^a   Oster, Gerry ^a  

^a POLICY ANALYSIS INC PAI   (United States)

^b PFIZER INC   (United States)

Author keywords

Fibromyalgia; Fibromyalgia syndrome; Fibromyositis; Fibromyositis syndrome; Fibrositis; Healthcare research

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIMIGRAINE AGENT; ANTIULCER AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; HYPNOTIC AGENT; LONG ACTING DRUG; MONOAMINE OXIDASE INHIBITOR; MUSCLE RELAXANT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; SHORT ACTING DRUG; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPTAN DERIVATIVE;

ABSENTEEISM; ADULT; AGE; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; FEMALE; FIBROMYALGIA; GENERAL PRACTITIONER; GERMANY; HEALTH CARE UTILIZATION; HEALTH PERSONNEL ATTITUDE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPATHY; PATIENT REFERRAL; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SEX;

AGED; ANALGESICS; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; FIBROMYALGIA; GERMANY; HEALTH SERVICES; HUMANS; MALE; MIDDLE AGED; PHYSICIANS, FAMILY; RETROSPECTIVE STUDIES;

EID: 53349153624     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802316550     Document Type: Article

References (44)

1. Wolfe F. The epidemiology of fibromyalgia. J Musculoskeletal Pain 1993;1:137-48
2. Campbell SM, Clark S, Tindall EA, et al. Clinical characteristics of fibrositis. I. A 'blinded', controlled study of symptoms and tender points. Arthritis Rheum 1983;26:817-24
3. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the multicenter criteria committee. Arthritis Rheum 1990;33:160-72
4. Goldenberg DL. Office management of fibromyalgia. Rheum Dis Clin North Am 2002;28:437-46
5. Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52:1264-73
6. Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005;119:5-15
7. Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004;50:2974-84
8. Tofferi JK, Jackson JL, O'Malley PG. Treatment of fibromyalgia with cyclobenzaprine: a meta-analysis. Arthritis Rheum 2004; 51:9-13
9. Arnold LM, Hess EV, Hudson JI, et al. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med 2002;112: 191-7
10. Goldenberg D, Mayskiy M, Mossey C, et al. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996;39: 1852-9
11. Carette S, Bell MJ, Reynolds WJ, et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. Arthritis Rheum 1994;37:32-40
12. Santandrea S, Montrone F, Sarzi-Puttini P, et al. A double-blind crossover study of two cyclobenzaprine regimens in primary fibromyalgia syndrome. J Int Med Res 1993;21:74-80
13. Russell IJ, Fletcher EM, Michalek JE, et al. Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam: a double-blind, placebo-controlled study. Arthritis Rheum 1991;34:552-60
14. Gendreau RM, Thorn MD, Gendreau JF, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 2005;32: 1975-85
15. Goldenberg DL. Fibromyalgia: treatment problems. J Musculo-skeletal Pain 1993;1:71-81
16. Lyrica (prescribing information). http://www.pfizer.com/files/products/ uspi_lyrica.pdf [Accessed 16/1/2007].
17. Dadabhoy D, Clauw DJ. Therapy insight: fibromyalgia - a different type of pain needing a different type of treatment. Nat Clin Pract Rheum 2006;2:364-72
18. Dadabhoy D, Clauw DJ. Fibromyalgia: progress in diagnosis and treatment. Curr Pain Headache Rep 2005;9:399-404
19. Rao SG, Clauw DJ. The management of fibromyalgia. Drugs Today 2004;40:539-54
20. Bombardier CH, Buchwald D. Chronic fatigue, chronic fatigue syndrome, and fibromyalgia: disability and health-care use. Med Care 1996;34:924-30
21. White KP, Speechley M, Harth M, et al. The London Fibromyalgia Epidemiology Study: comparing the demographic and clinical characteristics in 100 random community cases of fibromyalgia versus controls. J Rheumatol 1999;26:1577-85
22. Wolfe F, Anderson J, Harkness D, et al. A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. Arthritis Rheum 1997;40:1560-70
23. Penrod JR, Bernatsky S, Adam V, et al. Health services costs and their determinants in women with fibromyalgia. J Rheumatol 2004;31:1391-8
24. Robinson RL, Bimbaum HG, Morley MA, et al. Economic cost and epidemiological characteristics of patients with fibromyalgia claims. J Rheumatol 2003;30:1318-25
25. Hughes G, Martinez C, Myon E, et al. The impact of a diagnosis of fibromyalgia on health care resource use by primary care patients in the UK: an observational study based on clinical practice. Arthritis Rheum 2006;54:177-83
26. Boonen A, van den Heuvel R, van Tubergen A, et al. Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylosis. Ann Rheum Dis 2005;64:396-402
27. Berger A, Dukes E, Martin S, et al. Characteristics and healthcare costs of patients with fibromyalgia syndrome. Int J Clin Pract 2007;61:1498-508
28. Dietlein G, Schroder-Bernhardi D. Use of the Mediplus patient database in healthcare research. Int J Clin Pharm Ther 2002; 40:130-3
29. World Health Organization. International statistical classification of diseases and related health problems, 10th revision: version for 2007. http://www.who.int/classifications/apps/icd/icd10online/ [Accessed 23/6/ 2008].
30. World Health Organization. Cancer pain relief. Geneva, Switzerland: World Health Organization; 1996.
31. Brant JM. Cancer-related neuropathic pain. Nurse Pract Forum 19981;9:154-62
32. Kanner R. Diagnosis and management of neuropathic pain in patients with cancer. Cancer Invest 2001;19:324-33
33. George RM, Ahmedzai SH. The management of neuropathic pain in cancer: clinical guidelines for the use of adjuvant analgesics. Indian J Cancer 2000;37:4-9
34. Allen RR. Neuropathic pain in the cancer patient. Neuropathic Pain Syndromes 1998;16:869-87
35. Katz N. Neuropathic pain in cancer and AIDS. Clin J Pain 2000;16:S41-S48
36. Arner S, Meyerson BA. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain 1988;33:11-23
37. Cohen KL, Harris S. Efficacy and safety of nonsteroidal anti-inflammatory drugs in the therapy of diabetic neuropathy. Arch Intern Med 1987;147:1442-4
38. Ripamonti C, Dickerson ED. Strategies for the treatment of cancer pain in the new millennium. Drugs 2001;61:955-77
39. Farrar JT, Portenoy RK. Neuropathic cancer pain: the role of adjuvant analgesics. Oncology 2001;15:1435-45
40. Oster G, Berger A, Dukes E, et al. Use of potentially inappropriate pain-related medications in older adults with painful neuropathic disorders. Am J Geriatr Pharmacother 20041;2:163-70
41. Berger A, Dukes EM, Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain 2004;5:143-9
42. Berger A, Dukes E, Mercadante S, et al. Use of antiepileptics and tricyclic antidepressants in cancer patients with neuropathic pain. Eur J Cancer Care 2006; 15:138-45
43. SAS proprietary software, release 8.4, SAS Institute Inc., Cary, NC.
44. Oliver K, Cronan TA, Walen HR, et al. Effects of social support and education on health care costs for patients with fibromyalgia. J Rheumatol 2001;28:2711-9